Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 3453.62
ONVO's Cash to Debt is ranked higher than
77% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.05 vs. ONVO: 3453.62 )
ONVO' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 3453.62

Equity to Asset 0.93
ONVO's Equity to Asset is ranked higher than
97% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. ONVO: 0.93 )
ONVO' s 10-Year Equity to Asset Range
Min: -7.39   Max: 0.96
Current: 0.93

-7.39
0.96
F-Score: 4
Z-Score: 104.65
M-Score: -4.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -6269.89
ONVO's Operating margin (%) is ranked lower than
56% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. ONVO: -6269.89 )
ONVO' s 10-Year Operating margin (%) Range
Min: -5448.28   Max: -5448.28
Current: -6269.89

Net-margin (%) -7663.71
ONVO's Net-margin (%) is ranked lower than
56% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.44 vs. ONVO: -7663.71 )
ONVO' s 10-Year Net-margin (%) Range
Min: -6820.05   Max: -6820.05
Current: -7663.71

ROE (%) -65.06
ONVO's ROE (%) is ranked higher than
52% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.43 vs. ONVO: -65.06 )
ONVO' s 10-Year ROE (%) Range
Min: -53.53   Max: -53.53
Current: -65.06

ROA (%) -60.78
ONVO's ROA (%) is ranked lower than
51% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.30 vs. ONVO: -60.78 )
ONVO' s 10-Year ROA (%) Range
Min: -3700   Max: -51.5
Current: -60.78

-3700
-51.5
ROC (Joel Greenblatt) (%) -2330.07
ONVO's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.19 vs. ONVO: -2330.07 )
ONVO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2409.45   Max: -2409.45
Current: -2330.07

» ONVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ONVO Guru Trades in

Q4 2013

ONVO Guru Trades in Q4 2013

Steven Cohen 12,600 sh (New)
» More
Q1 2014

ONVO Guru Trades in Q1 2014

Paul Tudor Jones 17,792 sh (New)
Steven Cohen Sold Out
» More
Q2 2014

ONVO Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ONVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.50
ONVO's P/B is ranked higher than
55% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.39 vs. ONVO: 12.50 )
ONVO' s 10-Year P/B Range
Min: 8.6   Max: 113.7
Current: 12.5

8.6
113.7
P/S 1404.60
ONVO's P/S is ranked lower than
52% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.12 vs. ONVO: 1404.60 )
ONVO' s 10-Year P/S Range
Min: 71   Max: 935
Current: 1404.6

71
935
EV-to-EBIT -21.88
ONVO's EV-to-EBIT is ranked lower than
57% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ONVO: -21.88 )
ONVO' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -21.88

Current Ratio 14.83
ONVO's Current Ratio is ranked higher than
97% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. ONVO: 14.83 )
ONVO' s 10-Year Current Ratio Range
Min: 0.04   Max: 34
Current: 14.83

0.04
34
Quick Ratio 14.80
ONVO's Quick Ratio is ranked higher than
97% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. ONVO: 14.80 )
ONVO' s 10-Year Quick Ratio Range
Min: 0.04   Max: 34
Current: 14.8

0.04
34

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.40
ONVO's Price/Net Cash is ranked higher than
86% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ONVO: 13.40 )
ONVO' s 10-Year Price/Net Cash Range
Min: 8.74   Max: 47.25
Current: 13.4

8.74
47.25
Price/Net Current Asset Value 13.15
ONVO's Price/Net Current Asset Value is ranked higher than
82% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ONVO: 13.15 )
ONVO' s 10-Year Price/Net Current Asset Value Range
Min: 8.74   Max: 47.25
Current: 13.15

8.74
47.25
Price/Tangible Book 12.68
ONVO's Price/Tangible Book is ranked higher than
62% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.63 vs. ONVO: 12.68 )
ONVO' s 10-Year Price/Tangible Book Range
Min: 8.49   Max: 34.36
Current: 12.68

8.49
34.36

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:4OR.Germany
Organovo Holdings Inc., is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types. Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine. Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development. Organovo's bioprinting technology can also be developed to create surgical tissues direct therapy.
» More Articles for ONVO

Headlines

Articles On GuruFocus.com
This 3D Printing Company Is a Solid Long-Term Buy Jul 26 2014 
Why Organovo Is a Better Buy Than 3D Systems May 14 2014 
Dump 3D Systems and Buy Organovo May 09 2014 
Why Organovo Is The Only 3D Printing Company Worth Buying Apr 25 2014 

More From Our Partners
Benzinga's M&A Chatter for Wednesday September 10, 2014 Sep 10 2014 - BENZINGA

More From Other Websites
Insider Trading Alert - BIG, PF And ONVO Traded By Insiders Sep 17 2014
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure Sep 15 2014
Organovo Holdings, Inc.'s Presentations Now Available for On-Demand viewing at... Sep 15 2014
Organovo Holdings, Inc.'s Presentations Now Available for On-Demand viewing at... Sep 15 2014
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure Sep 11 2014
Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com September 11 Sep 09 2014
Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com September 11 Sep 09 2014
Organovo to Present at the Morgan Stanley Global Healthcare Conference Sep 05 2014
NASDAQ, NYSE, TSX, and OTC-listed Companies Webcast Live to Investors: September 11 at... Sep 05 2014
Organovo Named 2015 Technology Pioneer by World Economic Forum Aug 26 2014
Global 3D bioprinting market pioneer Organovo named as 2015 Technology Pioneer by World Economic... Aug 25 2014
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Aug 21 2014
ORGANOVO HOLDINGS, INC. Financials Aug 15 2014
3 Stocks Under $10 to Trade for Breakouts Aug 13 2014
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 12 2014
Organovo Highlights Liver Toxicology Achievement, Reports Q1 Fiscal 2015 Results Aug 12 2014
ORGANOVO HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report Aug 08 2014
Organovo Announces Appointment of Gregory T. Lucier as Corporate Advisor Aug 06 2014
4 Stocks Under $10 Moving Higher Aug 06 2014
HighTech Set To Disrupt the BioTech Industry Aug 01 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK